AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
First-in-class TDP-43 antibody developed using SurpraAntigen™ platformThe only TDP-43 antibody with reported in vivo activityLAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) […]